| [1] |
Minturn JE, Fryer HJ, Geschwind DH, et al. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth[J]. J Neurosci, 1995, 15(10): 6757-6766.
|
| [2] |
Goshima Y, Nakamura F, Strittmatter P, et al. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33[J]. Nature, 1995, 376(6540): 509-514.
|
| [3] |
Ricard D, Rogemond V, Charrier E, et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a-sensitive oligodendrocytes[J]. J Neurosci, 2001, 21(18): 7203-7214.
|
| [4] |
Chakraborty G, Kumar S, Mishra R, et al. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model[J]. PLoS ONE, 2012, 7(3): e33633.
|
| [5] |
Zou Y. Does planar cell polarity signaling steer growth cones?[J].Curr Top Dev Biol, 2012, 101(6): 141-160.
|
| [6] |
Hotta A, Inatome R, Yuasa-Kawada J, et al. Critical role of collapsin response mediator protein-associated molecule CRAM for filopodia and growth cone development in neurons[J]. Mol Biol Cell, 2005, 16(1): 32-39.
|
| [7] |
Gong X, Tan M, Gao Y, et al. CRMP5 interacts with actin to regulate neurite outgrowth[J]. Mol Med Rep, 2016, 13(2): 1179-1185.
|
| [8] |
Shih JY, Lee YC, Yang SC, et al. Collapsin response mediator protein-1: a novel invasion-suppressor gene[J]. Clin Exp Metastasis, 2003, 20(1): 69-76.
|
| [9] |
Hou H, Chen L, Zha Z, et al. Long form collapsin response mediator protein-1 promotes the migration and invasion of osteosarcoma cells[J]. Oncol Lett, 2016, 12(1): 23-28.
|
| [10] |
Moutal A, White KA, Chefdeville A, et al. Dysregulation of CRMP2 Post-Translational Modifications Drive Its Pathological Functions[J]. Mol Neurobiol, 2019, 56(10): 6736-6755.
|
| [11] |
Quach TT, Wilson SM, Rogemond V, et al. Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation[J]. J Cell Sci, 2013, 126(18): 4262-4273.
|
| [12] |
Guo H, Xia B. Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer[J]. BMC Cancer, 2016, 16(1): 565.
|
| [13] |
Zheng C, Guo K, Chen B, et al. miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5[J]. Cancer Biomark, 2019, 26(2): 193-202.
|
| [14] |
Zhou K, Yang Y, Gao L, et al. NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study[J]. Schizophr Bull, 2012, 38(3): 579-591.
|
| [15] |
Lin YS, Lin YF, Chen KC, et al. Collapsin response mediator protein 5 (CRMP5) causes social deficits and accelerates memory loss in an animal model of Alzheimer's disease[J]. Neuropharmacology, 2019, 157(1): 107673.
|
| [16] |
Wang L, Liu W, Tang H, et al. DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma[J].Cancer Med, 2017, 6(5):982-993.
|
| [17] |
Moutal A, Honnorat J, Massoma P, et al. CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling[J]. Cancer Res, 2015, 75(17): 3519-3528.
|
| [18] |
Meyronet D, Massoma P, Thivolet F, et al. Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma[J]. Am J Surg Pathol, 2008, 32(11): 1699-1708.
|
| [19] |
Fukada M, Watakabe I, Yuasa-Kawada J, et al. Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family[J].J Biol Chem, 2000, 275(48):37957-37965.
|
| [20] |
Inatome R, Tsujimura T, Hitomi T, et al. Identification of CRAM, a novel unc-33 gene family protein that associates with CRMP3 and protein-tyrosine kinase(s) in the developing rat brain[J]. J Biol Chem, 2000, 275(35): 27291-27302.
|
| [21] |
Veyrac A, Giannetti N, Charrier E, et al. Expression of collapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system[J]. Eur J Neurosci, 2005, 21(10): 2635-2648.
|
| [22] |
Lauzi J, Anders F, Liu H, et al. Neuroprotective and neuroregenerative effects of CRMP-5 on retinal ganglion cells in an experimental in vivo and in vitro model of glaucoma[J]. PLoS ONE, 2019, 14(1): e0207190.
|
| [23] |
Camdessanché JP, Ferraud K, Boutahar N, et al. The collapsin response mediator protein 5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interactions[J]. J Neuropathol Exp Neurol, 2012, 71(4): 298-311.
|
| [24] |
Yamashita N, Mosinger B, Roy A, et al. CRMP5 (collapsin response mediator protein 5) regulates dendritic development and synaptic plasticity in the cerebellar Purkinje cells[J]. J Neurosci, 2011, 31(5): 1773-1779.
|
| [25] |
Brot S, Rogemond V, Perrot V, et al. CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2[J]. J Neurosci, 2010, 30(32): 10639-10654.
|
| [26] |
Naudet N, Moutal A, Vu H N, et al. Transcriptional regulation of CRMP5 controls neurite outgrowth through Sox5[J]. Cell Mol Life Sci, 2018, 75(1): 67-79.
|
| [27] |
Brot S, Smaoune H, Youssef-Issa M, et al. Collapsin response-mediator protein 5 (CRMP5) phosphorylation at threonine 516 regulates neurite outgrowth inhibition[J]. Eur J Neurosci, 2014, 40(7): 3010-3020.
|
| [28] |
Ji Z, Zhang G, Chen L, et al. Spastin Interacts with CRMP5 to Promote Neurite Outgrowth by Controlling the Microtubule Dynamics[J]. Dev Neurobiol, 2018, 78(12): 1191-1205.
|
| [29] |
Takahashi S, Inatome R, Yamamura H, et al. Isolation and expression of a novel mitochondrial septin that interacts with CRMP/CRAM in the developing neurones[J]. Genes Cells, 2003, 8(2): 81-93.
|
| [30] |
Brot S, Auger C, Bentata R, et al. Collapsin response mediator protein 5 (CRMP5) induces mitophagy, thereby regulating mitochondrion numbers in dendrites[J]. J Biol Chem, 2014, 289(4): 2261-2276.
|
| [31] |
Zekeridou A, Majed M, Heliopoulos I, et al. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments[J]. Thorac Cancer, 2019, 10(4): 1001-1004.
|
| [32] |
Lancaster E. Paraneoplastic Disorders[J].Continuum (Minneap Minn), 2015, 23(6): 1653-1679.
|
| [33] |
Cohen DA, Bhatti MT, Pulido JS, et al. Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema[J].Ophthalmology, 2020, 127(2): 221-229.
|
| [34] |
Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study[J].Neurology, 2015, 85(3): 235-239.
|
| [35] |
Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases[J]. Neurology, 2018, 90(2): 103-110.
|
| [36] |
Kunchok A, Zekeridou A, Pittock S. CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy[J]. JAMA Neurol, 2020, 77(2): 255-256.
|
| [37] |
Li H, Zhang A, Hao Y, et al. Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report[J]. Medicine (Baltimore), 2018, 97(19): e0696.
|
| [38] |
Tada S, Furuta M, Fukada K, et al. Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneoplastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8): 907-910.
|
| [39] |
Ha J, Na BS, Ahn JH, et al. Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine[J]. Tremor Other Hyperkinet Mov (N Y), 2019, 9(10): 1-4.
|
| [40] |
Ibrahim Ismail I, K John J, Ibrahim M, et al. Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent[J]. Case Rep Neurol, 2020, 12(1): 50-55.
|
| [41] |
Brot S, Malleval C, Benetollo C, et al. Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation[J]. Exp Cell Res, 2013, 319(5): 588-599.
|
| [42] |
Misaghi A, Goldin A, Awad M, et al. Osteosarcoma: a comprehensive review[J]. Sicot j, 2018, 4(12): 1-8.
|
| [43] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J].CA Cancer J Clin, 2020, 70(1): 7-30.
|
| [44] |
Aliprandi A, Terruzzi A, Rigamonti A, et al. Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma[J].Neurol Sci, 2015, 36(8): 1501-1503.
|
| [45] |
Delgado C, Vergara RC, Martínez M, et al. Neuropsychiatric symptoms in alzheimer's disease are the main determinants of functional impairment in advanced everyday activities[J]. J Alzheimers Dis, 2019, 67(1): 381-392.
|
| [46] |
Chater TE, Goda Y. The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity[J]. Front Cell Neurosci, 2014, 8(11): 401.
|
| [47] |
Mirnics K, Middleton FA, Lewis DA, et al. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse[J].Trends Neurosci, 2001, 24(8): 479-486.
|
| [48] |
Kitagawa K, Nagai T, Yamada K. Pharmacological and proteomic analyses of neonatal polyI:C-treated adult mice[J]. Neurosci Res, 2019, 147(10): 39-47.
|